Skip to content
Subscriber Only

NewLink-Merck Ebola Vaccine Trial Resumes in Geneva After Pause

A trial of NewLink Genetics Corp.’s experimental Ebola vaccine will resume in Geneva today, using a lower dosage to avoid the joint pain that led researchers to suspend tests last month.

The remaining 56 volunteers in the 115-person trial will receive 300,000 vaccine particles, compared with a dose of as many as 50 million particles that were given during the first part of the project, University Hospitals of Geneva said in a statement today. Final results are expected in March.